ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
66 951,04
0,01%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. XBiotech Inc (XBIT)

  7. XBiotech Inc (XBIT) Actualités

XBIT

XBiotech (XBIT)

XBiotech Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:XBIT
DateHeureSourceTitreSymboleSociété
10/05/202417h27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
07/02/202418h36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
05/01/202416h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XBITXBiotech Inc
04/01/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XBITXBiotech Inc
04/01/202415h00GlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
14/11/202315h00GlobeNewswire Inc.Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisNASDAQ:XBITXBiotech Inc
26/09/202315h00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeNASDAQ:XBITXBiotech Inc
30/08/202315h00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic CancerNASDAQ:XBITXBiotech Inc
08/08/202317h47GlobeNewswire Inc.XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialNASDAQ:XBITXBiotech Inc
26/06/202314h48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
23/06/202321h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
20/06/202315h20Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:XBITXBiotech Inc
22/05/202315h00GlobeNewswire Inc.FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsNASDAQ:XBITXBiotech Inc
17/05/202315h22Edgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:XBITXBiotech Inc
17/05/202315h00GlobeNewswire Inc.XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesNASDAQ:XBITXBiotech Inc
10/05/202321h42Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XBITXBiotech Inc
28/04/202318h38Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:XBITXBiotech Inc
28/04/202318h33Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XBITXBiotech Inc
10/02/202318h22Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
13/10/202218h46GlobeNewswire Inc.XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal CancerNASDAQ:XBITXBiotech Inc
20/06/202215h00GlobeNewswire Inc.XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer StudyNASDAQ:XBITXBiotech Inc
13/05/202221h17Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XBITXBiotech Inc
28/04/202215h00GlobeNewswire Inc.XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal CanceNASDAQ:XBITXBiotech Inc
15/03/202222h02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XBITXBiotech Inc
02/02/202215h00GlobeNewswire Inc.XBiotech Inks Clinical Manufacturing DealNASDAQ:XBITXBiotech Inc
13/12/202114h00GlobeNewswire Inc.FDA Approves XBiotech’s IND in RheumatologyNASDAQ:XBITXBiotech Inc
28/10/202117h59GlobeNewswire Inc.XBiotech to Launch Novel Candidate Therapy for StrokeNASDAQ:XBITXBiotech Inc
08/09/202115h00GlobeNewswire Inc.Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic CancerNASDAQ:XBITXBiotech Inc
30/08/202115h00GlobeNewswire Inc.XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical DirectorNASDAQ:XBITXBiotech Inc
30/07/202117h03GlobeNewswire Inc.XBiotech Announces Payment of Dividend to Holders of Common StockNASDAQ:XBITXBiotech Inc
 Showing the most relevant articles for your search:NASDAQ:XBIT

Dernières Valeurs Consultées

BOV
ASAI3
Sendas Distribuidora ON
BOV
RCSL4Q
RECRUSUL PN
LSE
PSH
Pershing Square
EU
MLMFI
Condor Technolog
CSE
RI
Royalties
EU
5871T
5871T
BOV
RCSL4
RECRUSUL PN
BOV
SNOP5L
Sinop Agro Quimica PNA
EU
P766S
P766S
LSE
DRTY
BOV
SNSY3
SANSUY ON
EU
S379S
S379S
BOV
RPMG3R
PET MANGUINH ON
BOV
RDOR3R
Rede DOr Sao Luiz ON
NASDAQ
VIRT
Virtu Financial
NASDAQ
XBIT
XBiotech
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés